Adage Capital Partners Gp, L.L.C. Alpine Immune Sciences, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 15, 2024	SELL	$17.75 - $41.6 $7.18 Million - $16.8 Million	-404,590 Reduced 56.62%	310,000 $12.3 Million
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $6.1 Million - $14.4 Million	714,590 New	714,590 $13.6 Million

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.